行情

CFRX

CFRX

ContraFect
NASDAQ

实时行情|Nasdaq Last Sale

5.76
-0.09
-1.54%
已收盘, 16:00 03/31 EDT
开盘
5.83
昨收
5.85
最高
6.19
最低
5.63
成交量
4.44万
成交额
--
52周最高
13.40
52周最低
2.693
市值
8,831.26万
市盈率(TTM)
-0.3723
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测CFRX价格均价为17.33,最高价位22.00,最低价为15.00。

EPS

CFRX 新闻

更多
  • 疫情冲击下 美零售巨头梅西百货临时解雇13万人
  • 观察者网 · 54分钟前
  • 纽约市长白思豪下令调查亚马逊 解雇仓库工人或违法
  • 新浪科技 · 57分钟前
  • 从-9%到-40%,一切预测都是瞎猜?
  • 新浪财经综合 · 1小时前
  • 别管美国经济是否会萎缩34%了,黄金月线出现了危险一幕
  • 新浪财经综合 · 1小时前

所属板块

生物技术和医学研究
-0.49%
制药与医学研究
-0.25%

热门股票

代码
价格
涨跌幅

CFRX 简况

ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapeutic protein and antibody products for the treatment of infectious diseases, including those caused by drug-resistant pathogens, particularly those treated in hospital settings. Its pipeline of lysin candidates includes CF-301, CF-302, CF-303, CF-309, CF-304, CF-305, CF-306, CF-307 and CF-308. Its other product candidate includes CF-404. Its lysin product candidate, CF-301 is developed for the treatment of Staph aureus bacteremia, including endocarditis, caused by methicillin-resistant Staph aureus and susceptible Staph aureus strains. Its product candidate, CF-404 is used for the treatment of human influenza, including seasonal and pandemic varieties. It focuses on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses.
展开

微牛提供ContraFect Corp(NASDAQ-CFRX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CFRX股票新闻,以帮助您做出投资决策。